Explanation of how the number of participants for analysis was determined.
Includes whether analysis was per protocol, intention to treat, or another method.
Also provides relevant details such as imputation technique, as appropriate.

Area under the serum concentration-time curve from time 0 to 21 days following the first dose of brentuximab vedotin

Time Frame

3 weeks

Population Description

Explanation of how the number of participants for analysis was determined.
Includes whether analysis was per protocol, intention to treat, or another method.
Also provides relevant details such as imputation technique, as appropriate.

All participants who received treatment

Reporting Groups

Description

Brentuximab Vedotin

Brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion

Measured Values

Brentuximab Vedotin

Participants Analyzed [Units: Participants]

102

Area Under the Curve [Units: Day * microgram/mL]Geometric Mean (Geometric Coefficient of Variation)